Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma

Wang,Dong; Luo,Liang; Chen,Wei; Chen,Lian-Zhou; Zeng,Wen-Tao; Li,Wen; Huang,Xiao-Hui

doi:10.3892/or.2013.2946

Significance of the vascular endothelial growth factor and the macrophage migration inhibitory factor in the progression of hepatocellular carcinoma

Authors:
- Dong Wang
- Liang Luo
- Wei Chen
- Lian-Zhou Chen
- Wen-Tao Zeng
- Wen Li
- Xiao-Hui Huang
View Affiliations

Affiliations: Department of Laboratory Medicine, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, P.R. China, Department of Medical Intensive Care Unit, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, P.R. China, Department of Hepatobiliary Surgery, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, P.R. China, Department of General Surgical Laboratory, The First Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510080, P.R. China
Published online on: December 23, 2013 https://doi.org/10.3892/or.2013.2946
Pages: 1199-1204

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression of vascular endothelial growth factor (VEGF) and macrophage migration inhibitory factor (MIF) in HCC progression and their correlation with clinicopathological factors as well as the relationship between their expression levels. The expression of serum VEGF and MIF was evaluated in 150 patients with HCC and in 30 normal volunteers by enzyme-linked immunosorbent assay (ELISA). VEGF and MIF expression levels were evaluated by immunohistochemistry on tissue microarrays containing 150 HCCs with paired adjacent non-cancer liver tissues. VEGF and MIF mRNA levels were determined by quantitative PCR in another 48 HCCs. The correlation of VEGF and MIF with clinicopathological factors was analyzed in HCC. Serum VEGF and MIF concentrations were higher in HCC patients than the levels in the controls. The expression levels of VEGF and MIF in the HCC tissues were both higher than those in the adjacent non-tumor liver tissues. Overexpression of VEGF and MIF was significantly associated with tumor size (P=0.027 and 0.022, respectively), intrahepatic metastasis (P=0.032 and 0.027, respectively), vascular invasion (P=0.044 and 0.039, respectively) and TNM stage (P=0.028 and 0.013, respectively). Furthermore, VEGF and MIF mRNA levels were higher in HCC compared to levels in the paired non-cancer liver tissues. VEGF and MIF mRNA levels were correlated with tumor stage and metastasis. The expression of VEGF was positively related with MIF expression in HCC. The expression of MIF and VEGF in HCC was markedly positively correlated, which suggests that MIF and VEGF play an important role in the progression of HCC. Both factors may concomitantly accelerate the progression of HCC.

View Figures

View References

1	Jemal A, Bray F, Center MM, Ferlay J, Ward E and Forman D: Global cancer statistics. CA Cancer J Clin. 61:69–90. 2011. View Article : Google Scholar
2	Hanahan D and Folkman J: Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 86:353–364. 1996. View Article : Google Scholar : PubMed/NCBI
3	Amini A, Masoumi Moghaddam S, Morris DL and Pourgholami MH: The critical role of vascular endothelial growth factor in tumor angiogenesis. Curr Cancer Drug Targets. 12:23–43. 2012. View Article : Google Scholar : PubMed/NCBI
4	Arcondéguy T, Lacazette E, Millevoi S, Prats H and Touriol C: VEGF-A mRNA processing, stability and translation: a paradigm for intricate regulation of gene expression at the post-transcriptional level. Nucleic Acids Res. 41:7997–8010. 2013.PubMed/NCBI
5	Ferrara N and Davis-Smyth T: The biology of vascular endothelial growth factor. Endocr Rev. 18:4–25. 1997. View Article : Google Scholar
6	Koukourakis MI, Papazoglou D, Giatromanolaki A, Bougioukas G, Maltezos E and Sivridis E: VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer. 46:293–298. 2004. View Article : Google Scholar : PubMed/NCBI
7	Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R, Henriksson R, Chen B, Pamula J, Pekala W, Zientek H, Rogozinska-Szczepka J, Utracka-Hutka B, Hallmans G and Försti A: Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 11:3647–3653. 2005. View Article : Google Scholar : PubMed/NCBI
8	Celen O, Kahraman I, Yildirim E and Berberoglu U: Correlation of vascular endothelial growth factor (VEGF) and CEA with clinicopathological variables in colorectal cancer patients. Neoplasma. 51:293–299. 2004.PubMed/NCBI
9	Shen YC, Hsu C and Cheng AL: Molecular targeted therapy for advanced hepatocellular carcinoma: current status and future perspectives. J Gastroenterol. 45:794–807. 2010. View Article : Google Scholar : PubMed/NCBI
10	Chen L, Shi Y, Jiang CY, Wei LX, Lv YL, Wang YL and Dai GH: Coexpression of PDGFR-alpha, PDGFR-beta and VEGF as a prognostic factor in patients with hepatocellular carcinoma. Int J Biol Markers. 26:108–116. 2011. View Article : Google Scholar : PubMed/NCBI
11	Ferrara N, Gerber HP and LeCouter J: The biology of VEGF and its receptors. Nat Med. 9:669–676. 2003. View Article : Google Scholar : PubMed/NCBI
12	Ren Y, Law S, Huang X, Lee PY, Bacher M, Srivastava G and Wong J: Macrophage migration inhibitory factor stimulates angiogenic factor expression and correlates with differentiation and lymph node status in patients with esophageal squamous cell carcinoma. Ann Surg. 242:55–63. 2005. View Article : Google Scholar : PubMed/NCBI
13	Greven D, Leng L and Bucala R: Autoimmune diseases: MIF as a therapeutic target. Expert Opin Ther Targets. 14:253–264. 2010. View Article : Google Scholar : PubMed/NCBI
14	Grieb G, Merk M, Bernhagen J and Bucala R: Macrophage migration inhibitory factor (MIF): a promising biomarker. Drug News Perspect. 23:257–264. 2010. View Article : Google Scholar : PubMed/NCBI
15	Meyer-Siegler KL, Iczkowski KA, Leng L, Bucala R and Vera PL: Inhibition of macrophage migration inhibitory factor or its receptor (CD74) attenuates growth and invasion of DU-145 prostate cancer cells. J Immunol. 177:8730–8739. 2006. View Article : Google Scholar : PubMed/NCBI
16	Ren Y, Chan HM, Fan J, Xie Y, Chen YX, Li W, Jiang GP, Liu Q, Meinhardt A and Tam PK: Inhibition of tumor growth and metastasis in vitro and in vivo by targeting macrophage migration inhibitory factor in human neuroblastoma. Oncogene. 25:3501–3508. 2006. View Article : Google Scholar : PubMed/NCBI
17	Ren Y, Tsui HT, Poon RT, Ng IO, Li Z, Chen Y, Jiang G, Lau C, Yu WC, Bacher M and Fan ST: Macrophage migration inhibitory factor: roles in regulating tumor cell migration and expression of angiogenic factors in hepatocellular carcinoma. Int J Cancer. 107:22–29. 2003. View Article : Google Scholar : PubMed/NCBI
18	Yang XW, Zhang LJ, Huang XH, Chen LZ, Su Q, Zeng WT, Li W and Wang Q: miR-145 suppresses cell invasion in hepatocellular carcinoma cells: miR-145 targets ADAM17. Hepatol Res. Apr 28–2013.(Epub ahead of print). View Article : Google Scholar
19	Namisaki T, Yoshiji H, Noguchi R, Ikenaka Y, Kitade M, Kaji K, Shirai Y, Aihara Y, Yoshii J, Yanase K, Tsujimoto T, Kawaratani H and Fukui H: The vascular endothelial growth factor (VEGF) receptor-2 is a major regulator of VEGF-mediated salvage effect in murine acute hepatic failure. J Angiogenes Res. 2:162010. View Article : Google Scholar : PubMed/NCBI
20	Hu J, Chen C, Su Y, Du J, Qian X and Jin Y: Vascular endothelial growth factor promotes the expression of cyclooxygenase 2 and matrix metalloproteinases in Lewis lung carcinoma cells. Exp Ther Med. 4:1045–1050. 2012.PubMed/NCBI
21	Li C, Liu B, Dai Z and Tao Y: Knockdown of VEGF receptor-1 (VEGFR-1) impairs macrophage infiltration, angiogenesis and growth of clear cell renal cell carcinoma (CRCC). Cancer Biol Ther. 12:872–880. 2011. View Article : Google Scholar : PubMed/NCBI
22	Yu W, Chen L, Yang YQ, Falck JR, Guo AM, Li Y and Yang J: Cytochrome P450 ω-hydroxylase promotes angiogenesis and metastasis by upregulation of VEGF and MMP-9 in non-small cell lung cancer. Cancer Chemother Pharmacol. 68:619–629. 2011.
23	Amano H, Ito Y, Suzuki T, Kato S, Matsui Y, Ogawa F, Murata T, Sugimoto Y, Senior R, Kitasato H, Hayashi I, Satoh Y, Narumiya S and Majima M: Roles of a prostaglandin E-type receptor, EP3, in upregulation of matrix metalloproteinase-9 and vascular endothelial growth factor during enhancement of tumor metastasis. Cancer Sci. 100:2318–2324. 2009. View Article : Google Scholar
24	Deng G, Zhao DL, Li GC, Yu H and Teng GJ: Combination therapy of transcatheter arterial chemoembolization and arterial administration of antiangiogenesis on VX2 liver tumor. Cardiovasc Intervent Radiol. 34:824–832. 2011. View Article : Google Scholar : PubMed/NCBI
25	Janani P, Sivakumari K, Geetha A, Yuvaraj S and Parthasarathy C: Bacoside A downregulates matrix metalloproteinases 2 and 9 in DEN-induced hepatocellular carcinoma. Cell Biochem Funct. 28:164–169. 2010. View Article : Google Scholar : PubMed/NCBI
26	David JR: Delayed hypersensitivity in vitro: its mediation by cell-free substances formed by lymphoid cell-antigen interaction. Proc Natl Acad Sci USA. 56:72–77. 1966. View Article : Google Scholar : PubMed/NCBI
27	Chesney J, Metz C, Bacher M, Peng T, Meinhardt A and Bucala R: An essential role for macrophage migration inhibitory factor (MIF) in angiogenesis and the growth of a murine lymphoma. Mol Med. 5:181–191. 1999.PubMed/NCBI
28	He XX, Yang J, Ding YW, Liu W, Shen QY and Xia HH: Increased epithelial and serum expression of macrophage migration inhibitory factor (MIF) in gastric cancer: potential role of MIF in gastric carcinogenesis. Gut. 55:797–802. 2006. View Article : Google Scholar : PubMed/NCBI
29	Bando H, Matsumoto G, Bando M, Muta M, Ogawa T, Funata N, Nishihira J, Koike M and Toi M: Expression of macrophage migration inhibitory factor in human breast cancer: association with nodal spread. Jpn J Cancer Res. 93:389–396. 2002. View Article : Google Scholar : PubMed/NCBI
30	Choudhary S, Hegde P, Pruitt JR, Sielecki TM, Choudhary D, Scarpato K, Degraff DJ and Pilbeam CC: Macrophage migratory inhibitory factor promotes bladder cancer progression via increasing proliferation and angiogenesis. Carcinogenesis. Aug 2–2013.(Epub ahead of print).
31	Bondza PK, Metz CN and Akoum A: Macrophage migration inhibitory factor up-regulates alpha(v)beta(3) integrin and vascular endothelial growth factor expression in endometrial adenocarcinoma cell line Ishikawa. J Reprod Immunol. 77:142–151. 2008. View Article : Google Scholar